- Conditions
- Head and Neck Cancer, Oral Complications, Radiation Toxicity
- Interventions
- sargramostim, quality-of-life assessment, radiation therapy
- Biological · Procedure · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- Not listed
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 217
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 167 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 292
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Head and Neck Cancer
- Interventions
- Fenretinide
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2004
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Head and Neck Cancer
- Interventions
- docetaxel, Gemcitabine
- Drug
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2012
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Gastric Cancer, Head and Neck Cancer, Kidney Cancer, Leukemia, Lung Cancer, Melanoma (Skin), Ovarian Cancer, Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- tanespimycin
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2005
- U.S. locations
- 2
- States / cities
- Los Angeles, California • New York, New York
- Conditions
- Head and Neck Cancer
- Interventions
- mutant p53 peptide pulsed dendritic cell vaccine, tetanus toxoid helper peptide, adjuvant therapy
- Biological · Procedure
- Lead sponsor
- Robert Ferris
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2014
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Head and Neck Cancer
- Interventions
- gefitinib, paclitaxel, radiation therapy
- Drug · Radiation
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2010
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland
- Conditions
- Nasopharyngeal Nonkeratinizing Carcinoma, Recurrent Nasopharynx Carcinoma, Stage III Nasopharyngeal Carcinoma AJCC v7, Stage IV Nasopharyngeal Carcinoma AJCC v7, Stage IVA Nasopharyngeal Carcinoma AJCC v7, Stage IVB Nasopharyngeal Carcinoma AJCC v7, Stage IVC Nasopharyngeal Carcinoma AJCC v7
- Interventions
- Laboratory Biomarker Analysis, Nivolumab
- Other · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2015
- U.S. locations
- 15
- States / cities
- Duarte, California • Los Angeles, California • Pasadena, California + 8 more
- Conditions
- Recurrent Nasopharyngeal Cancer, Stage IV Nasopharyngeal Cancer
- Interventions
- bortezomib, gemcitabine hydrochloride, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Salivary Gland Squamous Cell Carcinoma, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IVA Salivary Gland Cancer, Stage IVA Squamous Cell Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVA Verrucous Carcinoma of the Larynx, Stage IVA Verrucous Carcinoma of the Oral Cavity, Stage IVB Salivary Gland Cancer, Stage IVB Squamous Cell Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVB Verrucous Carcinoma of the Larynx, Stage IVB Verrucous Carcinoma of the Oral Cavity, Stage IVC Salivary Gland Cancer, Stage IVC Squamous Cell Carcinoma of the Larynx, Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Oropharynx, Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVC Verrucous Carcinoma of the Larynx, Stage IVC Verrucous Carcinoma of the Oral Cavity, Tongue Cancer, Untreated Metastatic Squamous Neck Cancer With Occult Primary
- Interventions
- cetuximab, placebo, sorafenib tosylate, laboratory biomarker analysis, quality-of-life assessment
- Biological · Other · Drug + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 8
- States / cities
- Tampa, Florida • Atlanta, Georgia • Baltimore, Maryland + 5 more
- Conditions
- Stage II Lymphoepithelioma of the Nasopharynx, Stage II Squamous Cell Carcinoma of the Nasopharynx, Stage III Lymphoepithelioma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Nasopharynx, Stage IV Lymphoepithelioma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Nasopharynx
- Interventions
- docetaxel, cisplatin, carboplatin, fluorouracil, 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy
- Drug · Radiation
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2020
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Verrucous Carcinoma of the Larynx, Stage III Verrucous Carcinoma of the Oral Cavity, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Verrucous Carcinoma of the Larynx, Stage IV Verrucous Carcinoma of the Oral Cavity
- Interventions
- erlotinib hydrochloride, intensity-modulated radiation therapy, pharmacogenomic studies, gene expression analysis, 3-dimensional conformal radiation therapy, biopsy, pharmacological study, laboratory biomarker analysis, questionnaire administration, enzyme-linked immunosorbent assay, polymorphism analysis
- Drug · Radiation · Other
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Nasopharyngeal Carcinoma, Castrate Resistant Prostate Cancer, Gastric Cancer, Ovarian Clear Cell Carcinoma, Mesothelioma, Sarcoma, Non Hodgkin Lymphoma, B Cell Lymphoma, Epithelioid Sarcoma
- Interventions
- APG-5918
- Drug
- Lead sponsor
- Ascentage Pharma Group Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Springdale, Arkansas
- Conditions
- Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma, Metastatic Nasopharyngeal Squamous Cell Carcinoma, Metastatic Oral Cavity Squamous Cell Carcinoma, Metastatic Oropharyngeal Squamous Cell Carcinoma, Metastatic Sinonasal Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Nasopharyngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Recurrent Sinonasal Squamous Cell Carcinoma, Squamous Cell Carcinoma of Unknown Primary, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Lip and Oral Cavity Cancer AJCC v8, Stage IV Nasopharyngeal Carcinoma AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IV Sinonasal Cancer AJCC v8
- Interventions
- Autologous Tumor Membrane Vesicles Vaccine, Biospecimen Collection, Computed Tomography, Echocardiography, Magnetic Resonance Imaging, Pembrolizumab, Positron Emission Tomography, Surgical Procedure
- Biological · Procedure
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia
- Conditions
- Bladder Cancer, Breast Cancer, Carcinoma of Unknown Primary, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Lung Cancer, Melanoma (Skin), Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Sarcoma
- Interventions
- filgrastim, docetaxel, gemcitabine hydrochloride
- Biological · Drug
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2005
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
- Conditions
- Nasopharyngeal Carcinoma, EBV-Related Gastric Carcinoma, EBV-Related Leiomyosarcoma, EBV Related Carcinoma, EBV-Related Sarcoma
- Interventions
- Nanatinostat, Valganciclovir, Pembrolizumab
- Drug
- Lead sponsor
- Viracta Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 3
- States / cities
- Stanford, California • Aurora, Colorado • Houston, Texas
- Conditions
- Carcinomas, Squamous Cell, Dysphagia
- Interventions
- Acupuncture
- Device
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Head and Neck Cancer
- Interventions
- protein expression analysis, proteomic profiling, immunoenzyme technique, laboratory biomarker analysis, liquid chromatography, mass spectrometry
- Genetic · Other
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2005
- U.S. locations
- 3
- States / cities
- Nashville, Tennessee
- Conditions
- Nasopharyngeal Cancer, EBV Infections
- Interventions
- EBV specific CTL Infusion, Anti CD45 monoclonal antibody
- Biological
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- Not listed
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Head and Neck Cancer
- Interventions
- cetuximab, cisplatin, fluorouracil, paclitaxel
- Biological · Drug
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 3
- States / cities
- Camden, New Jersey • Lakewood, New Jersey • Long Branch, New Jersey
- Conditions
- Head and Neck Cancer, Mucositis Oral, Radiation Toxicity, Tongue Cancer
- Interventions
- sargramostim, oral salt and soda mouthwash
- Biological · Other
- Lead sponsor
- Marilyn Dodd
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Nasopharyngeal Carcinoma, Stage III Nasopharyngeal Carcinoma AJCC v8, Stage IVA Nasopharyngeal Carcinoma AJCC v8, Nasopharyngeal Cancer, Nasopharyngeal Cancer Stage
- Interventions
- Intensity-Modulated Radiation Therapy (IMRT), Radiographic Imaging, Biospecimen Collection
- Radiation · Procedure
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Drug/Agent Toxicity by Tissue/Organ, Head and Neck Cancer, Radiation Toxicity
- Interventions
- amifostine trihydrate, cisplatin, paclitaxel, radiation therapy
- Drug · Radiation
- Lead sponsor
- University of Illinois at Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1997
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Squamous Cell Carcinomas
- Interventions
- Reduced Dose Radiation, Standard Dose Radiation, Carboplatin
- Radiation · Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2035
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Head and Neck Cancer, Pain
- Interventions
- acupuncture therapy, standard follow-up care
- Procedure
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 1
- States / cities
- New York, New York